bpc 157 human clinical trials evidence 2025 BPC-157 and the Difference Between an Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 as a Healing Peptide

AOD-9604 is administered subcutaneously with a half-life of approximately 23 hours in humans (measured in Phase 2 trials), also requiring daily dosing

Glutathione 1,500mg Summary Description: Glutathione is a master antioxidant peptide essential for protecting cells from oxidative damage, detoxifying harmful substances, and supporting a robust immune system

Store the lyophilised powder at 20C, protected from light and moisture

For an exploration of sub-threshold dosing approaches, our microdosing tirzepatide chart covers the calculations for ultra-low doses

It is not intended for human or veterinary use, diagnosis, treatment or self-administration